Ryan J. Sullivan, MD, discusses the role of checkpoint inhibitors in the treatment landscape for patients with melanoma.
Ryan J. Sullivan, MD, assistant professor of medicine, Harvard Medical School, assistant professor of hematology/oncology, Massachusetts General Hospital, discusses the role of checkpoint inhibitors in the treatment landscape for patients with melanoma.
Over the last decade, patients with both adjuvant and metastatic melanoma have had limited options until the last decade when immune checkpoint inhibitors were introduced to this space, says Sullivan. These advances include the approval of ipilimumab (Yervoy), nivolumab (Opdivo), and pembrolizumab (Keytruda), among others.
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More